Patent · US Active

Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein

US10752675B2 · kind B2 · utility

0Cited by
0References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 14, 2017
Grant dateAug 25, 2020
Priority date
Expiry dateNov 14, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/76
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.